| Outcome Measures: |
Primary: Number of Participants With Adverse Events [Safety and Tolerability of GLY-200], Safety and tolerability will be assessed by incidence of adverse events (AEs). Clinically significant changes from baseline in vital signs, clinical laboratory parameters, and electrocardiograms (ECGs) will be recorded as AEs., Over the 14-day treatment period | Secondary: Change From Baseline in Fasting Glucose, Evaluate change from baseline (Day 1) in fasting glucose as captured via continuous glucose monitoring (CGM) at Week 1 and Week 2, Day 1, Day 7, and Day 14|Change From Baseline in Fasting Plasma Insulin, Evaluate change from baseline in fasting plasma insulin at Day 1, Day 7, and Day 14, Day 1, Day 7, and Day 14|Change From Baseline in 3-hours Postprandial Plasma Glucose Profile, Evaluate change from baseline in Area Under the Curve (AUC) glucose during mixed meal tolerance tests (MMTTs) at Day 1, Day 7, and Day 14. AUC is calculated from -60 to 180 min using the trapezoidal rule., Day 1, Day 7, and Day 14|Change From Baseline in 3-hours Postprandial Plasma Insulin Profile, Evaluate change from baseline in Area Under the Curve (AUC) insulin during mixed meal tolerance tests (MMTTs) at Day 1, Day 7, and Day 14. AUC is calculated from -60 to 180 min using the trapezoidal rule., Day 1, Day 7, and Day 14
|
